Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exploratory tocilizumab study in Takayasu's arteritis stratified by autoantibody type
jRCTs021210077Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Sep 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of tocilizumab in Takayasu arteritis (TAK) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Started Sep 2022; status: completed.
02
Drugs
tocilizumab
03
Conditions
Takayasu arteritis (TAK)
Beyond the preview
Go deeper on jRCTs021210077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210077.